GNHAY - Vifor Pharma to acquire Sanifit Therapeutics and Inositec AG

Vifor Pharma (OTCPK:GNHAY) announces the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing non-dialysis treatments for soft tissue and vascular calcification disorders. Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472. Shareholders of Sanifit will receive an upfront payment of €205M, milestone payments for up to €170M and tiered sales-based milestones that could reach mid to high triple digit Euro millions at peak sales. Vifor Pharma will acquire 100% of the shares in Inositec AG, receiving full global rights for the lead asset INS-3001. Inositec will receive an upfront payment of CHF20M and be eligible for success based clinical earn-out payments in the low triple digit million range. Closing of the Sanifit

For further details see:

Vifor Pharma to acquire Sanifit Therapeutics and Inositec AG